PETALING JAYA: ACE Market-listed Kanger International Bhd has signed 10-year lease agreements for two of its commercial buildings in Ganzhou City in China.
The initial rental income per year for both commercial buildings will amount to RM11.1mil, subject to scheduled rent increases, the company said in a statement.
The commercial buildings comprise a purpose-built six-storey one-stop “AutoCity” building with a net lettable area (NLA) of 493,062 sq ft and a 19-storey hotel with 190,715 sq ft of NLA.
Both buildings are owned by Kanger’s indirect wholly-owned subsidiary, Ganzhou Kanger Industrial Co Ltd and have a combined NLA of 683,777 sq ft, the statement added.
Can you imagine how many small hotels are there in China? There are hundreds of towns and billions of people to cater for. --------------------------------------------------------------------------------
In 2018, the group secured the exclusive distributorship in China for the Classen brand of laminated hardwood flooring from Classen GmbH, Germany.
With rising acceptance of the Classen brand in China, Kanger was recently presented with the Excellence Award for Best Supplier to the Chinese Bed & Breakfast Industry at the 2019 International B&B Industry Development Forum and the 2019-2020 Illustrious Brand award by the China Renovation & Construction Alliance.
Sales of Classen products have been encouraging and proved to be a good complement to the group, generating revenue to the group whilst the group scaled down its production of in-house bamboo products to make way for the relocation exercise of the bamboo plant.
Zuellig Pharma is one of the largest healthcare services groups in Asia and our purpose is to make healthcare more accessible. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started almost a hundred years ago and has grown to become a US$13 billion business covering 13 markets with over 12,000 employees. Our people serve over 350,000 medical facilities and work with over 500 clients, including the top 20 pharmaceutical companies in the world.
More recently, we launched our Zuellig Health Solutions Innovation Centre to develop new services and address some pressing healthcare needs in Asia. Since then, our teams have been focused on creating data, digital and disease management solutions, supporting patients with chronic conditions and helping payors manage healthcare costs.
"Untuk memudahkan penyimpanan, pengendalian dan pengedaran vaksin yang selamat, kumpulan bekerjasama dengan Zuellig Pharma Sdn Bhd (Zuellig Pharma), pengedar vaksin terbesar di Malaysia dan Asia.
"Zuellig Pharma adalah salah satu pemegang lesen yang diberikan kerajaan untuk pengedaran vaksin dan mempunyai kemampuan penyimpanan serta pengedaran.
so kanger today can green. All the kanger potential businesses revealed today. correct?
future potential business beyond 2021
bamboo eco-tourism bamboo foodstuff bamboo other by-products
Posted by my2020 > Dec 8, 2020 10:44 PM | Report Abuse
next year prospects: 1. higher income from bamboo flooring rmb200mil per annum up to rmb600 for 3 yrs 2. glove. 1bil unit per annum 3. rental rm11 mil per annum for 10 yrs 4. vaccine unknown qty 5. sand export unlimited qty? 6. nanotech anti covid coating solution
"2. Wuhan Institute of Biological Products / Sinopharm, and
3. Beijing Institute of Biological Products / Sinopharm
No, you didn’t read wrong. The two points above are because one company has two vaccine candidates undergoing trials at two different facilities.
The state-owned China National Pharmaceutical Group Co, Ltd (Sinopharm) is conducting Phase III clinical tests for two vaccine candidates developed by Wuhan Institute of Biological Products and Beijing Institute of Biological Products respectively, with testing involving two dosages given 21 days apart.
On November 17, GI Healthcare Resources Sdn Bhd, which is partnering Sinopharm, said the vaccine candidates are undergoing Phase 3 clinical trials involving more than 55,000 individuals in 10 countries including the UAE, Bahrain, Egypt, Morocco.
The Malaysian company also noted that the emergency use of the two vaccine candidates have been approved in China, the UAE and Bahrain for over one million frontliners.
GI Healthcare also proposed to sponsor 10,000 of Sinopharm’s vaccines — which can be stored between 2 to 8 degrees Celsius — for emergency use in Malaysia by frontliners."
One thing you need to remember when trading or investing in ANY stocks is that the amount of money that you use should be the amount of money that you are willing to lose or let go. In the stock market, nothing is 100% certain and there are bound to be risks. So the money i am using for Kanger is my spare cash which i am willing to lose. Hence, up or down, no worries for me. I will just leave it there for one year.
@see2sea Yes, certainly not for short term or contra traders. Those who always complain in this forum are most probably short term or contra traders. They do not have holding power....
Indonesia expects halal certificate for experimental COVID-19 vaccine
Indonesia's highest Muslim clerical body is expected to issue a halal certification for the experimental COVID-19 vaccine developed by China-based Sinovac Biotech, officials said on Monday (Dec 7)
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Noobie123
1,661 posts
Posted by Noobie123 > 2020-12-09 08:37 | Report Abuse
Kanger to facilitate sand exports to mainland China, Hong Kong
https://www.theedgemarkets.com/article/kanger-facilitate-sand-exports-mainland-china-hong-kong